Skip to main content

Advertisement

SpringerLink
Log in

MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

The study was aimed at investigating the association between MDR-1 genetic polymorphisms [C1236T, G2677T(A), C3435T] and parameters describing the clinical course and treatment response of childhood steroid-responsive nephrotic syndrome (SRNS). Three MDR-1 genetic markers were analyzed in 108 children diagnosed with SRNS and in 135 healthy controls with neither allergic nor renal disease. All subjects were genotyped by PCR-restriction fragment length polymorphism (RFLP) analysis, and an EM algorithm-based analysis was utilized to estimate haplotype frequencies. As expected, there was no difference in genotypic and allelic distribution between and among SRNS patients and healthy children. However, all individual polymorphisms were strongly associated with time to response to initial prednisone therapy. The frequencies of the mutated alleles were higher in late responders (time to remission: >7 days) to oral prednisone (0.53, 0.52,0.66) than in early responders (time to remission: <7 days; 0.24, 0.19, 0.32), with all p values <0.001 for positions 1236, 2677 and 3435, respectively). Odds ratios (ORs) reflecting the strength of the associations were as follows: 6.79 (95% CI:1.96– 23.54) for 1236 T/T, 13.7 (95% CI:2.78–67) for 2677 T/T and 9.92 (95% CI: 3.01–32.71) for 3435 T/T as compared to the respective-wild type homozygotes. The TTT haplotype was similarly found to be significantly associated with late oral steroid response (0.49 vs. 0.19, p=0.0003). Variants 1236T, 2677TA and 3435T identify patients that respond slower to oral prednisone. Although the functional properties of the substitutions investigated here are still to be determined, our findings may be a small step toward the optimization of immunosuppressive therapy in SRNS children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J (2000) Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 105:1242–1249

    Article  CAS  Google Scholar 

  2. Ahmad H, Tejani A (2000) Predictive value of repeat renal biopsies in children with nephrotic syndrome. Nephron 84:342–346

    Article  CAS  Google Scholar 

  3. Lande MB, Gullion C, Hogg RJ, Gauthier B, Shah B, Leonard MB, Bonilla-Felix M, Nash M, Roy S 3rd, Strife CF, Arbus G (2003) Long versus standard initial steroid therapy for children with the nephrotic syndrome. A report from the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 18:342–634

    PubMed  Google Scholar 

  4. Sakaeda, T, Nakamura T, Okumura K (2004) Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr Top Med Chem 4:1385–1398

    Article  CAS  Google Scholar 

  5. Dilger K, Schwab M, Fromm MF (2004) Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis 10:578–583

    Article  Google Scholar 

  6. Farrell RJ, Menconi MJ, Keates AC, Kelly CP (2002) P-glycoprotein-170 inhibition significantly reduces cortisol and cyclosporin efflux from human intestinal epithelial cells and T lymphocytes. Aliment Pharmacol Ther 16:1021–1031

    Article  CAS  Google Scholar 

  7. Klimecki WT, Futscher BW, Grogan TM, Dalton WS (1994) P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 83:2451–2458

    Article  CAS  Google Scholar 

  8. Stachowski J, Zanker CB, Runowski D, Zaniew M, Peszko A, Medynska A, Zwolinska D, Rogowska-Kalisz A, Hyla-Klekot L, Szprygner K, Weglarska J, Sieniawska M, Musial W, Maciejewski J, Baldamus CA (2000) Resistance to therapy in primary nephrotic syndrome: effect of MDR1 gene activity. Pol Merkuriusz Lek 8:218–221

    CAS  Google Scholar 

  9. Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L (2004) P-glycoprotein in autoimmune diseases. Autoimmun Rev 3:188–192

    Article  CAS  Google Scholar 

  10. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, Tanaka Y (2004) Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells 9:1265–1273

    Article  CAS  Google Scholar 

  11. Raghu G, Park SW, Roninson IB, Mechetner EB (1996) Monoclonal antibodies against P-glycoprotein, an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 24:1258–1264

    CAS  PubMed  Google Scholar 

  12. Gollapud S, Gupta S (2001) Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol 21:420–340

    Article  CAS  Google Scholar 

  13. Ieiri I, Takane H, Otsubo K (2004) The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 43:553–576

    Article  CAS  Google Scholar 

  14. Woodahl EL, Ho RJ (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5:11–19

    Article  CAS  Google Scholar 

  15. Soranzo N, Cavalleri GL, Weale ME, Wood NW, Depondt C, Marguerie R, Sisodiya SM, Goldstein DB (2004) Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res 14:1333–1344

    Article  CAS  Google Scholar 

  16. Kabuki N, Okugawa T, Hayakawa H, Tomizawa S, Kasahara T, Uchiyama M (1998) Influence of age at onset on the outcome of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 12:467–470

    Article  CAS  Google Scholar 

  17. Constantinescu AR, Shah HB, Foote EF, Weiss LS (2000) Predicting first-year relapses in children with nephrotic syndrome. Pediatrics 105:492–495

    Article  CAS  Google Scholar 

  18. Takeda A, Takimoto H, Mizusawa Y, Simoda M (2001) Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 16:888–893

    Article  CAS  Google Scholar 

  19. Nasi M. Aedelmann CM, Berstein J, Barnett HL (1992) The nephrotic syndrome. In: Edelmann CM, Berstein J, Meadow SR, Spitzer A, Travis LB (eds) Pediatric kidney disease, vol 2. Little, Brown and Company, Boston, pp 1247–1266

  20. International Study of Kidney Disease in Children (1982) Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children. J Pediatr 101:514–518

    Article  Google Scholar 

  21. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie (1987) Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 62:1102–1106

    Article  Google Scholar 

  22. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174

    Article  CAS  Google Scholar 

  23. Imani S, Jusko WJ, Steiner R (1999) Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. Pediatr Transplant 3:126–130

    Article  CAS  Google Scholar 

  24. Rostin M, Barthe P, Houin G, Alvinerie M, Bouissou F (1990) Pharmacokinetics of prednisolone in children with the nephrotic syndrome. Pediatr Nephrol 4:470–473

    Article  CAS  Google Scholar 

  25. Gatti G, Perucca E, Frigo GM, Notarangelo LD, Barberis L, Martini A (1984) Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission. Br J Clin Pharmacol 17:423–431

    Article  CAS  Google Scholar 

  26. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, Kay AB (1991) Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 144:1016–1025

    Article  CAS  Google Scholar 

  27. Magee MH, Blum RA, Lates CD, Jusko WJ (2002) Pharmacokinetic /pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation. Br J Clin Pharmacol 53:474–484

    Article  CAS  Google Scholar 

  28. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y (2005) Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 52:1676–1683

    Article  CAS  Google Scholar 

  29. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, Bowman P, Burckart GJ (2002) The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Hum Immunol 63:765–770

    Article  CAS  Google Scholar 

  30. Asano T, Takahashi KA, Fujioka M, Inoue S, Okamoto M, Sugioka N, Nishino H, Tanaka T, Hirota Y, Kubo T (2003) ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 13:675–682

    Article  CAS  Google Scholar 

  31. Sakaeda T (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 20:391–414

    Article  CAS  Google Scholar 

  32. Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E (2006) MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 79: 325–338

    Article  CAS  Google Scholar 

  33. Kurzawski M, Pawlik A, Gornik W, Drozdzik M (2006) Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep 58:35–40

    CAS  Google Scholar 

  34. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199

    Article  CAS  Google Scholar 

  35. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clark AG (2003) Pharmacogenetics of Membrane Transporters Investigators. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13:481–494

    Article  CAS  Google Scholar 

  36. Morita N, Yasumori T, Nakayama K (2003) Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities. Biochem Pharmacol 65:1843–1852

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. I Department of Pediatrics, Medical University of Białystok, ul. Waszyngtona 17, 15-274, Białystok, Poland

    Anna Wasilewska & Walentyna Zoch-Zwierz

  2. Department of Clinical Molecular Biology, Medical University of Białystok, Białystok, Poland

    Grzegorz Zalewski & Lech Chyczewski

Authors
  1. Anna Wasilewska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grzegorz Zalewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lech Chyczewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walentyna Zoch-Zwierz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Wasilewska.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wasilewska, A., Zalewski, G., Chyczewski, L. et al. MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol 22, 44–51 (2007). https://doi.org/10.1007/s00467-006-0275-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-006-0275-3

Keywords

Search

Navigation